Lifeboat Foundation

(repeat) Are you ready to defer all your personal decision-making to machines? Polls show that most Americans are uneasy about the unchecked growth of artificial intelligence. The possible misuse of genetic engineering also makes us anxious. We all have a stake in the responsible development of science and technology, but fortunately, science fiction films can help.

The movies Ex Machina and Jurassic Park suggest where A.I. and unfettered gene-tinkering could lead. But even less popular sci-fi movies can help us imagine unsettling scenarios regarding over-population, smart drugs, and human cloning.

And not all tales are grim. The 1951 film, The Man in the White Suit, weaves a humorous story of materials science run amok.

Lux Capital, a New York-based venture capital firm, has raised more than $1 billion across two new funds to back companies on “the cutting edge of science.” The firm raised $500 million for its sixth flagship early-stage fund and another $550 million for an opportunity fund focused on growth-stage investments. Limited partners include global foundations, university endowments, and tech billionaires.

Lux also announced a new hire: Deena Shakir, formerly of GV (Google Ventures), has joined as an investment partner.

To the regular person, Lux’s investments are considered moonshot. The firm has backed entrepreneurs that are working on everything from neurostimulation to nuclear energy to synthetic biology. During my last interview with co-founder and managing partner Josh Wolfe, I actually called one of his portfolio companies “freaking crazy.”

Over 4000 patients in the United States alone are waiting for a heart transplant, while millions of others worldwide need hearts but are ineligible for the waitlist. The need for replacement organs is immense, and new approaches are needed to engineer artificial organs that are capable of repairing, supplementing, or replacing long-term organ function.

A team of researchers from Carnegie Mellon University has published a paper in Science that details a new technique allowing anyone to 3D bioprint tissue scaffolds out of collagen, the major structural protein in the human body. This first-of-its-kind method brings the field of tissue engineering one step closer to being able to 3D print a full-sized, adult human heart.

The technique, known as Freeform Reversible Embedding of Suspended Hydrogels (FRESH), has allowed the researchers to overcome many challenges associated with existing 3D bioprinting methods, and to achieve unprecedented resolution and fidelity using soft and living materials.

Continue reading “3D printing the human heart” »

In a paper published in the July 31 issue of Science Translational Medicine, researchers at Fred Hutchinson Cancer Research Center used CRISPR-Cas9 to edit long-lived blood stem cells to reverse the clinical symptoms observed with several blood disorders, including sickle cell disease and beta-thalassemia.

It’s the first time that scientists have specifically edited the genetic makeup of a specialized subset of adult blood stem cells that are the source of all cells in the blood and immune system.

The proof-of-principle study suggests that efficient modification of targeted stem cells could reduce the costs of gene-editing treatments for blood disorders and other diseases while decreasing the risks of unwanted effects that can occur with a less discriminating approach.

Mr. Epstein’s vision reflected his longstanding fascination with what has become known as transhumanism: the science of improving the human population through technologies like genetic engineering and artificial intelligence. Critics have likened transhumanism to a modern-day version of eugenics, the discredited field of improving the human race through controlled breeding.

Mr. Epstein, the accused sex trafficker, was fascinated by eugenics. He told scientists and others of his vision of using his New Mexico ranch to impregnate women.

The co-inventor of the groundbreaking gene editing technology talks to OneZero about a world where illness could be diagnosed in minutes.

But getting human cells to grow in another species is not easy. Nakauchi and colleagues announced at the 2018 American Association for the Advancement of Science meeting in Austin, Texas that they had put human iPS cells into sheep embryos that had been engineered not to produce a pancreas. But the hybrid embryos, grown for 28 days, contained very few human cells, and nothing resembling organs. This is probably because of the genetic distance between humans and sheep, says Nakauchi.

The research could eventually lead to new sources of organs for transplant, but ethical and technical hurdles need to be overcome.

Medicine has a “Goldilocks” problem. Many therapies are safe and effective only when administered at just the right time and in very precise doses – when given too early or too late, in too large or too small an amount, medicines can be ineffective or even harmful. But in many situations, doctors have no way of knowing when or how much to dispense.

Now, a team of bioengineers led by UC San Francisco’s Hana El-Samad, PhD, and the University of Washington’s David Baker, PhD, have devised a remarkable solution to this problem – “smart” cells that behave like tiny autonomous robots which, in the future, may be used to detect damage and disease, and deliver help at just the right time and in just the right amount.